NASDAQ · EDIT
Editas Medicine, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EDIT: Nov 9, 2026
Editas Medicine, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.28.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.19 | $-0.25 | 5 |
| Dec 2026 | $-0.18 | $-0.08 | $-0.24 | 4 |
| Mar 2027 | $-0.23 | $-0.20 | $-0.28 | 3 |
| Jun 2027 | $-0.24 | $-0.20 | $-0.29 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · MarketBeat- Zacks · Oct 9, 10:53 AM EDTEDIT Set to Begin First-in-Human Study in HypercholesterolemiaEditas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
- Fintel · Oct 8, 7:15 PM EDTWells Fargo Upgrades Editas Medicine to Overweight from Equal-WeightFintel reports that on October 8, 2026, Wells Fargo upgraded their outlook for Editas Medicine (NASDAQGS:EDIT) (LSE:0IFK) from Equal-Weight to Overweight.Editas Medicine, Inc., based in the United States, operates within the biotechnology sector and is notable for its pioneering
- RTTNews · Oct 8, 8:45 AM EDTEditas Advances Gene-Editing Program Into First Human Study For High Cholesterol(RTTNews) – Editas Medicine, Inc. (EDIT) has received regulatory and ethics approval in Australia to begin the first-in-human Phase 1/2 clinical trial of EDIT-401, an experimental gene editing therapy designed to treat hyperlipidemia, or high levels of LDL cholesterol.
- Fintel · Sep 23, 5:10 PM EDTGuggenheim Upgrades Editas Medicine to Buy from NeutralFintel reports that on September 23, 2026, Guggenheim upgraded their outlook for Editas Medicine (NASDAQGS:EDIT) (DB:8EM) from Neutral to Buy.Editas Medicine, Inc., based in the United States, operates within the biotechnology sector and is notable for its pioneering efforts in g
- MarketBeat · Sep 11, 9:01 PM EDTEditas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy2 gene-editing stocks reshaping hereditary disease treatments Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholest
- MarketBeat · Sep 9, 7:02 AM EDTEditas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-4012 gene-editing stocks reshaping hereditary disease treatments Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, C
- RTTNews · Sep 8, 8:37 AM EDTEditas Medicine Names Dan Ory Chief Medical Officer(RTTNews) – U.S. gene editing company Editas Medicine Inc. (EDIT), announced on Tuesday that it has appointed Biotechnology Executive Dan Ory as Chief Medical Officer, effective September 8.
- Zacks · Sep 4, 11:30 AM EDTEditas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 24, 9:59 AM EDT4 Gene-Editing Biotech Stocks Worth Watching for Long-Term GainsCRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
- Zacks · Aug 10, 9:40 AM EDTIs Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
- RTTNews · Aug 7, 9:45 AM EDTEditas Posts Narrower Loss In Q2, Expects Phase 1/2 Data For EDIT-401 In Q1 Of '27; Stock Up(RTTNews) – Editas Medicine, Inc. (EDIT) a clinical-stage gene editing company developing in vivo CRISPR gene-editing medicines for genetic diseases, reported a narrower net loss for the second quarter, primarily attributable to higher collaboration and other research and develop
- Zacks · Aug 6, 11:26 AM EDTEDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in FocusEditas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Editas Medicine, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.